WELCOME TO The Biotechnology REPORT
Covid-19 Vaccine Distribution System
April 14, 2021
I'm For Real
Enter your details once to access all our information and resources
GFBiochemicals brings biobased levulinic acid to market through technology innovation. Founded in 2008, GFBiochemicals is the first company to produce levulinic acid at commercial scale directly from biomass.
whitePaper | November 4, 2019
Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023
whitePaper | September 17, 2021
The adoption of CAR T therapies in the UK NHS is a success story, especially seen in
relation to the experience in many other countries. The UK NHS showed itself to be agile,
and responsive to addressing the unique challenges these therapies present, which
facilitated access to patients earlier than in many other countries. (including delivery centre
selection, development of service specifications, collaboration with manufacturers
throughout the preparation phase for adoption, establishment of national multidisciplinary
CAR T team to ensure equity of access and prioritization of resources (where needed)).
whitePaper | November 14, 2019
SmartExtraction significantly simplifies the entire automated workflow of DNA extraction, setting new standards with regard to efficiency, yield and quality of the DNA.
whitePaper | July 30, 2021
Clinical trials are complex, lengthy, and resource-inefficient. The clinical research industry is responsible for the delivery of medical solutions to society by systematically evaluating their safety and efficacy in humans during so-called clinical trials. As exemplified by the COVID-19 pandemic, a steady and efficient influx of vaccines, therapeutics, and other innovative medical solutions is critical for meeting society’s current and future medical needs. Unfortunately, the industry faces several persistent issues that make clinical trial operations overly complex, lengthy, and resource-inefficient.
whitePaper | April 8, 2020
The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.
whitePaper | April 7, 2020
The Internet of Things (IoT) could not be timelier for biotech/pharma. With fierce cost pressures, the push for value-based outcomes, and the need for flexible manufacturing solutions, the IoT is the much-needed shot in the arm to bring about transformational change. Sensors, actuators, and devices (“things”) embedded in production equipment and networked through computer systems can generate an enormous amount of data. The data can be mined for insights and opportunities to drive production efficiency, automate monitoring and controlling functions, and enable flexible manufacturing systems.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE